跳至主要内容
临床试验/EUCTR2008-000990-39-LV
EUCTR2008-000990-39-LV进行中(未招募)不适用

Reduction of the gingival inflammation by V0109 DI. Randomised, parallel groups, double blind study, V0109 DI versus placebo, in patients presenting gingivitis.

PIERRE FABRE MEDICAMENT0 个研究点目标入组 54 人开始时间: 2008年6月19日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
54

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Will be eligible patients (male or female) who meet the following criteria:
  • - age between 18 and 45 years inclusive,
  • - negative urine pregnancy test at inclusion for woman of child bearing potential and using an efficient contraceptive (oral contraception, intrauterine device, tubal ligature) since at least 2 months before the screening and until 1 month after the end of the study,
  • - stable hormonal contraception since least 2 months before the screening visit and not start it during the study,
  • - be non smoker,
  • - have a minimum of 20 natural teeth ( excluding wisdom teeth) and good dental health (except gingivitis),
  • - have a toothbrush and toothpaste,
  • - have gingivitis (Gingival Index > or equal to 1,5),
  • - willing and able to understand and sign an approved Informed Consent Form,
  • - able to understand the protocol and to attend the control visits,
  • - registered with a social security or health insurance system if required by law.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Will not be included patients who have one of the following criteria:
  • * Criteria related to pathology
  • - periodontitis,
  • - history of periodontitis or acute necrotizing ulcerative gingivitis,
  • - history of severe medical or psychiatric disease/disorder which, in the judgement of the investigator, puts the patient « at risk » or is likely to modify the handling of the study drug,
  • - epilepsy,
  • - any coagulation disorder,
  • - hyposialia or asialia,
  • - caries with cavities and ill-fitting restorations,
  • - lichen planus,
  • - current signs or symptoms of mucosal tissue ulcerations, or canker sores,
  • *Criteria related to treatments
  • - currently undergoing orthodontic treatment,
  • - extensive interproximal restorations, crowns, bridges or implants,
  • - treatment within the six weeks preceding inclusion with either :·antibiotics·corticosteroids·non-steroidal anti-inflammatory drugs·immunosuppressive drugs, immunostimulant drug, antimitotic drug,
  • - start or change within the preceding month of any drug which could interfere with salivary flow: anticholinergic drug, atropine, scopolamine, quaternar amoniums, imipraminic antidepressives, sedative antihistamines, phenothiazines neuroleptics, disopyramide,
  • - treatment with any other topical product (i.e. mouthwashes, gels,…) which could interfere with the study treatment,
  • * Criteria related to the way of life
  • - Drinking excessive amounts of alcohol (more than 2 glass of wine (>2) per day or equivalent),
  • - history of drug addiction,
  • * Criteria related to the population
  • - female who is pregnant or breast feeding or not using contraception, or planning to become pregnant,
  • - participation to an other clinical trial in the previous month before the inclusion visit or during the study,
  • - patient who is not able to understand the information (for linguistic or psychiatric reasons) and to give informed consent,
  • - patient who has forfeited his/her freedom by administrative or legal decision, or who is under guardianship,

研究者

相似试验